Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.

Siddharth SinghN N AndersenM AnderssonE V LoftusTine Jess

Published in: Alimentary pharmacology & therapeutics (2017)

In this population-based, propensity score matched, real-life cohort study using administrative claims, there was no significant difference in effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD.

Keyphrases

rheumatoid arthritis
ulcerative colitis
disease activity
juvenile idiopathic arthritis
health insurance
hidradenitis suppurativa
clinical evaluation